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Abstract
Background: EGFR mutation-induced cell proliferation causes changes in tumor biology and tumor metabolism,
which may reflect tumor marker concentration and 18F-FDG uptake on PET/CT. Direct aspirates of primary lung
tumors contain different concentrations of tumor markers than serum tumor markers, and may correlate better with
EGFR mutation than serum tumor markers.
The purpose of this study is to investigate an association between cytologic tumor markers and FDG uptake with
EGFR mutation status in non-small cell lung cancer (NSCLC).
Methods: We prospectively collected tumor aspirates of 61 patients who underwent EGFR mutation analysis. Serum
and cytologic CYFRA 21-1, CEA, and SCCA levels were measured and correlated with EGFR gene mutations. FDG
PET/CT was performed on 58 patients for NSCLC staging, and SUV was correlated with EGFR mutation status.
Results: Thirty (50 %) patients had EGFR mutation and 57 patients had adenocarcinoma subtype. Univariate analysis
showed that female gender, never smoker, high levels of cytologic CYFRA 21-1 (c-CYFRA) and lower maximum
standard uptake value (SUVmax) were correlated with EGFR mutations. ROC generated cut-off values of 20.8 ng/ml
for c-CYFRA and SUVmax of 9.6 showed highest sensitivity for EGFR mutation detection. Multivariate analysis
revealed that female gender [hazard ratio (HR): 18.15, p = 0.025], higher levels of c-CYFRA (HR: 7.58, and lower
SUVmax (HR: 0.08, p = 0.005) were predictive of harboring EGFR mutation.
Conclusions: The cytologic tumor marker c-CYFRA was positively associated with EGFR mutations in NSCLC. EGFR
mutation-positive NSCLCs have relatively lower glycolysis compared with NSCLCs without EGFR mutation.
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Background
Discovery of certain epidermal growth factor receptor
(EGFR) mutations that affect tyrosine kinase inhibitor
(TKI) efficacy in non-small cell lung carcinoma (NSCLC)
has increased the importance of identifying patients
harboring EGFR mutations. TKIs have been shown to
prolong progression-free survival, and activating EGFR
mutations have been shown to predict the response
to EGFR-TKI therapy [1–3]. Sociopathological factors
predicting EGFR mutations are Asian descent, female
gender, and never-smokers; however, patient selection
for EGFR mutation analysis cannot be made on these
factors alone [2].
Serum tumor markers such as carcinoembryonic anti-
gen (CEA), squamous cell carcinoma antigen (SCCA),
and cytokeratin 19 fragments (CYFRA 21-1) are clinic-
ally used for NSCLC screening and recurrence evalu-
ation, and some of these tumor markers have been
shown to be correlated with prognostic factors such as
higher TNM stages [4, 5]. Although none of these tumor
markers have been correlated with EGFR mutation
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status, CYFRA 21-1 has been shown to be useful in the
prediction of TKI response in EGFR mutation patients,
suggesting a potential correlation between CYFRA 21-1
and EGFR mutation status [6, 7].
Recently, we have shown that tumor markers derived
from cytologic fluid aspirated from the primary lung
cancer site can be clinically useful in the differential
diagnosis of lung cancer and NSCLC subtyping [8–10].
We have shown that there is a weak correlation between
cytologic tumor markers and their serum counterparts,
which suggests an additional mechanism for their re-
lease into the serum. Although no studies thus far have
shown a correlation between serum tumor marker
levels and EGFR mutation status, in vitro studies using
hepatocellular carcinoma and head and neck cancer
cell lines have shown an EGF-dependent increase in
cytokeratin 19 [11, 12].
Increased fluorine-18-flurodeoxyglucose (FDG) uptake
in lung cancers has been shown to be a prognostic factor
for NSCLC patients, and lower SUV has been reported
to be associated with favorable outcomes in EGFR tar-
geted therapy [13]. These findings suggest a potential
correlation between FDG uptake with EGFR mutation
and serum tumor markers. However, the correlation be-
tween FDG uptake with EGFR mutation have not been
satisfactorily evaluated.
Therefore, we conducted this study to prospectively
investigate an association between cytologic tumor




From April 2009 to November 2012, a total of 440 pa-
tients suspected of primary lung malignancy were pro-
spectively enrolled for fine-needle aspiration biopsy
(FNAB) of lung nodules or masses and to evaluate cyto-
logic tumor marker levels in needle aspirates. The inclu-
sion criteria were age greater than 20 years, lesion size
more than 8 mm, and solid lesions (ground glass opacity
component less than 50 %). The exclusion criteria were
ground glass opacity lesions (n = 24) and refusal to
provide informed written consent (n = 29). Of these
440 patients, 253 had NSCLC pathology, 96 had be-
nign lesions, 18 had metastasis or small cell lung can-
cer pathology, and 20 had indeterminate results. To
test the application of cytologic tumor markers in the
prediction of EGFR mutations, only patients (n = 253)
with lesions pathologically confirmed to be NSCLC
were included. Finally, 61 patients were included (33 men
and 28 women; average age 61 ± 10 years) who underwent
EGFR mutation analysis and had pathologically confirmed
NSCLC (Fig. 1).
The charts of these 61 patients were reviewed to evaluate
for age, gender, smoking history, pack year, and TNM sta-
ging. Never-smoker was defined as less than patients who
smoked less than 100 cigarettes in their lifetime or patients
who stopped smoking for more than 15 years prior to the
study and who smoked less than ten packs of cigarettes
per year. Former smoker was defined as more than
3 months of smoking cessation before lung cancer
Fig. 1 Study design and patient selection algorithm
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diagnosis. fluorine-18-flurodeoxyglucose positron emis-
sion tomography/computed tomography (FDG PET/CT)
was performed in the staging workup of NSCLC to
evaluate for N- and M-staging. Of the 61 patients,
semi-quantitative FDG uptake evaluation was not pos-
sible in three patients due to the PET/CT having been
obtained at other hospitals. All other FDG PET/CT
scans were obtained before surgery or further treatment.
Data collection was systematized and a standardized regis-
tration form was prepared. This study was approved by
the institutional ethics committee of Yonsei University
College of Medicine, and all patients provided informed
written consent.
Percutaneous transthoracic needle aspiration biopsy
technique
The biopsy procedures were performed by three experi-
enced chest radiologists, who had more than 4 years of
experience in performing thoracic biopsies. Fluoroscopy-
guided biopsy interventions (n = 21) and CT-guided
biopsy interventions (n = 40) were performed using previ-
ously stated methods [9]. Briefly, one needle puncture was
used to obtain at least two aspiration specimens which
were separated into two components for cytological
examination and cell block processing. Remaining aspi-
rates (1–2 cc) were rinsed with 1 mL of normal saline
solution in a tube for the evaluation of cytological tumor
markers.
Tumor marker analysis
Tumor markers analyzed were serum CYFRA 21-1
(s-CYFRA), serum CEA (s-CEA), serum SCCA (s-SCCA),
cytologic CYFRA 21-1 (c-CYFRA), cytologic CEA (c-CEA),
and cytologic SCCA (c-SCCA). All serum samples
and cytological fluid aspirates were collected prior to
any therapy. Serum and cytological fluid analyses
were performed using the same methods as previously
described [9]. Serum samples were obtained within 1 or
2 days of FNAB. Cytological fluid samples were assayed
twice for tumor marker levels, and the mean values were
used for analysis. Detectable levels for each cytological fluid
tumor marker were defined as follows: 0.1–500 ng/ml for
CYFRA 21-1 and CEA, and 0.01–150 ng/ml for SCCA.
PET/CT protocol and imaging analysis
All patients underwent routine FDG PET/CT scans
with either Discovery 600 PET/CT (GE Healthcare,
Milwaukee, WI, USA) or Biograph TruePoint 40 PET/
CT (Siemens Medical Systems, CTI, Knoxville, TN,
USA). All patients fasted for at least 6 h and glucose
levels in peripheral blood in all patients were con-
firmed to be 140 mg/dl or less before FDG injection.
Approximately 5.5 MBq/kg of FDG was administered
intravenously 1 h before image acquisition. After the
initial low-dose CT (Discovery 600: 30 mA, 130 kVp;
Biograph TruePoint: 36 mA, 120 kVp), standard PET
imaging was performed from the skull base to the
proximal thighs with an acquisition time of 3 min/bed in
three-dimensional mode. Images were then reconstructed
using the ordered subset expectation maximization
algorithm (two iterations, 20 subsets).
All PET/CT images were reviewed by an experienced
nuclear medicine specialist on one GE AW 4.0 worksta-
tion (GE Healthcare, Milwaukee, WI, USA). Identification
of the aspirated primary lesion was done by reviewing
images obtained during biopsy. On PET scans, a volume
of interest (VOI) was drawn on the primary lesion. The
maximum standard uptake value (SUVmax) of the pri-
mary lesion was then obtained and recorded. Total lesion
glycolysis (TLG) of the primary lesion was also obtained
by using an isocontour of 40 %; if the VOI was out of pro-
portion to the lesion seen on CT, either a cut-off SUV of
2.5 was used or the threshold was adjusted to best fit the
contour of the lesion on CT. TLG was calculated by the
multiplication of volume (cm3) with the mean SUV within
the VOI.
EGFR mutation analysis
Genetic analysis was performed to determine activating
EGFR mutations in exon 19, exon 20, or exon 21. The
nucleotide sequence of the kinase domain of the EGFR
gene, from exon 18 to 21, was determined using nested
polymerase chain reaction amplification of the individual
exons, as previously described [14, 15].
Statistical analysis
EGFR mutation status was used as a reference standard
for analysis. Categorical variables (smoking status, gen-
der, TNM staging, and pathology) were analyzed by
either the chi-squared test or the Fisher’s exact test.
Continuous variables (age, serum and cytologic tumor
marker levels, SUVmax, and TLG) were first evaluated
for normality using the Kolmogorov-Smirnov test, and
p-values > 0.05 were assumed to fulfill the normality as-
sumption. Due to the wide distribution of TLG values
(range: 1.1–787.8), natural logarithmic transformations
were applied to TLG (renamed to log(TLG)) to obtain
normally distributed data (fulfill the Kolmogorov-Smirnov
assumption). Parametric analyses was used for normally
distributed variables, otherwise non-parametric analyses
were used. The Student’s t-test was used to compare aver-
age values of tumor marker and FDG parameters accord-
ing to EGFR status.
Receiver operating characteristic (ROC) curves were con-
structed using the continuous variables that showed signifi-
cant differences in the average values on t-test. A cut-off
value was determined for the highest sensitivity for predict-
ing EGFR mutations. A logistic regression model was then
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used to evaluate the association between clinicopathologic
factors with an EGFR mutation. Statistically significant find-
ings on univariate analysis were used in the multivariate
analysis. P values of less than 0.05 were considered statisti-
cally significant. All statistical analyses were carried out
using SAS (version 9.2, SAS Inc., Cary, NC, USA), with the
exception of Medcalc (version 9.5, MedCalc, Mariakerke,
Belgium) which was used for the ROC analysis.
Results
Patient demographics
A total of 61 patients (28 female, mean age 61 years) were
included in this study. EGFR mutations were identified in
30 patients (49.1 %), of which most had either an exon 19
deletion (n = 18), exon 21 mutation (n = 10), or exon 20
mutation (n = 2). A significantly higher portion of female
distribution (20 of 30 patients, p = 0.001) and never
smokers (21 out of 30, p = 0.007) were seen among pa-
tients harboring an EGFR mutation. The major pathology
of the lesions was adenocarcinoma (n = 58), whereas two
patients had squamous cell pathology and one patient had
NSCLC not otherwise specified. The TNM stage in this
study population was nearly equally distributed, with 26
patients at TNM stage I/II, and 35 patients at TNM stage
III/IV. There was no significant difference in TNM staging
between the patients harboring the different EGFR muta-
tions. Patient demographics are shown in Table 1.
EGFR status and tumor marker levels
There was no significant difference in serum tumor marker
levels between wild-type and mutant EGFR (7.3 ng/ml vs
2.5 ng/ml for s-CYFRA, 18.8 ng/ml vs 34.6 ng/ml for
s-CEA, and 1.0 ng/ml vs 0.8 ng/ml for s-SCCA). In
regards to cytologic tumor markers, only c-CYFRA was
significantly different between EGFR status, with higher
levels of c-CYFRA with EGFR mutations compared with
wild-type EGFR (200.2 ng/ml ± 208.8 ng/ml vs 85.2 ng/ml
±135.8 ng/ml, p = 0.014). Other cytologic tumor markers
showed no significant differences between EGFR status
(21.6 ng/ml vs 50 ng/ml for c-CEA and 10 ng/ml vs
5.7 ng/ml for c-SCCA) (Table 1).
ROC analysis evaluating the c-CYFRA cut-off value
that best predicts EGFR mutations resulted in 20.8 ng/ml
for the highest sensitivity of 83.3 % [95 % confidence inter-
val (CI): 65.3–94.3, area under the curve (AUC) = 0.715,
p = 0.001) (Fig. 2a). Using this cut-off, 18 out of 23 pa-
tients (78 %) with low c-CYFRA levels were wild-type
EGFR, and 25 out of 38 patients (65.8 %) with high c-
CYFRA levels had mutant EGFR, resulting in an overall
specificity of 58.1 % and an overall accuracy of 70.5 %.
EGFR status and PET/CT results
The average SUVmax was significantly lower in EGFR-
mutated lesions compared to wild-type (7.0 ± 3.9 vs 10.3 ±
5.8, p = 0.014), and log(TLG) was lower in EGFR-mutated
lesions (1.80 ± 0.65 vs 1.35 ± 0.70, p = 0.014). Figure 3
shows representative images of patients with 18F-FDG
uptake according to EGFR status. The correlation between
c-CYFRA and FDG uptake using Pearson correlation
showed no significant correlation between the two (0.001
for SUVmax, p = 0.996, and -0.049 for log(TLG), p = 0.79).
ROC analysis resulted in 9.6 as the cut-off for SUV-
max with the highest sensitivity for predicting an EGFR
mutation (sensitivity 79.3, 95 % CI: 60–92, AUC = 0.68,
p = 0.010) (Fig. 2b). Using this cut-off, 23 out of 29
patients (79.3 %) with EGFR mutations had low FDG
uptake, and 15 out of 29 patients (51.7 %) had high FDG
uptake in EGFR wild-types, with an overall accuracy of
65.5 %. For log(TLG), a cut-off of 1.64 showed highest
sensitivity in predicting EGFR mutation. Using this
cut-off, compared to SUVmax, log(TLG) showed lower
sensitivity (72.4 %) and slightly increased accuracy (69.0 %)
in predicting EGFR mutation.
Multivariate analysis in predicting EGFR mutation
Significant variables predicting EGFR mutations were
gender, smoking status, c-CYFRA, SUVmax, and
log(TLG). These variables were used in the multivariate
analysis for predicting an EGFR mutation (Table 2).
Two models were used due to multicollinearity between
Table 1 Patient characteristics
Variable Wild-type EGFR EGFR mutation p-value
Age 63.1 ± 7.8 60.3 ± 11.8 0.282
Gender (F:M) 8:23 20:10 0.001a
Pathology (ADC:SCC:NOS) 28:1:1 29:1:0 0.611
Smoking status 0.007a
Never smoker 11 21
Current/former smoker 20 9
TNM staging (1:2:3:4) 8:7:5:11 7:4:5:14 0.746
Tumor markers
s-CYFRA 7.28 ± 20.28 2.50 ± 1.67 0.201
s-CEA 18.77 ± 46.91 34.61 ± 67.55 0.300
s-SCCA 1.00 ± 1.03 0.84 ± 0.89 0.507
c-CYFRA 85.18 ± 135.79 200.19 ± 208.84 0.014a
c-CEA 21.60 ± 59.05 49.85 ± 110.04 0.214
c-SCCA 9.97 ± 35.36 5.70 ± 19.33 0.562
SUVmax 10.33 ± 5.82 7.01 ± 3.91 0.014a
Log(TLG) 1.80 ± 0.65 1.35 ± 0.70 0.014a
ADC adenocarcinoma, c-CEA cytologic carcinoembryonic antigen, c-CYFRA cytologic
CYFRA 21-1, c-SCCA cytologic squamous cell carcinoma antigen, NOS non-small cell
carcinoma not otherwise specified, SCC squamous cell carcinoma, s-CEA serum
carcinoembyonic antigen, s-CYFRA serum CYFRA 21-1, s-SCCA serum squamous cell
carcinoma antigen, SUVmax maximum standard uptake value, log(TLG) natural
logarithmic transformation of total lesion glycolysis
astatistically significant values of p < 0.05
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SUVmax and log(TLG). Of these variables, female
gender [hazard ratio (HR): 18.15, 95 % CI: 1.44–228.7,
p = 0.025], higher levels of c-CYFRA (HR: 7.58, 95 % CI:
1.57–36.61, p = 0.012), lower FDG uptake (HR: 13.00,
95 % CI: 2.20–76.62, p = 0.005), and lower log(TLG) (HR:
24.15, 95 % CI: 0–0.38, p = 0.005) were significantly corre-
lated with EGFR mutations.
Discussion
We have shown a positive correlation between c-CYFRA
and EGFR mutation status in predominately solid-type
NSCLC. C-CYFRA levels higher than 20.8 ng/ml have
83.3 % sensitivity and 70.5 % accuracy in predicting
EGFR mutation status. In addition, we have also shown
that these solid type NSCLCs showed lower FDG uptake
Fig. 2 Receiver operating characteristic (ROC) curves of c-CYFRA level and FDG uptake (SUVmax) in predicting EGFR mutations. a ROC of c-CYFRA
showed that a cut-off of 20.8 ng/ml had the highest sensitivity of 83.3 % (area under the ROC curve = 0.715, p = 0.001) in discriminating EGFR
mutations from wild-type EGFR. b ROC of FDG uptake showed that a SUVmax cut-off of 9.6 had the highest sensitivity of 79.3 % in predicting
EGFR mutations (area under the ROC curve = 0.68, p = 0.010)
Fig. 3 Representative figures of differences in FDG uptake according to EGFR status. a A 55 yo female with 21 mm sized adenocarcinoma in the
right lower lung superior segment. SUVmax was 2.2, and TLG was 4.0. b A 58 yo female with 20 mm sized adenocarcinoma in the left upper lung
apical segment. SUVmax was 14.6, and TLG was 31.5
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(7.0 ± 3.9) in EGFR mutation-positive lesions compared
with EGFR wild-type (10.3 ± 5.8).
In our study, we evaluated three widely used serum
tumor markers in NSCLC and their cytologic counter-
parts to evaluate for EGFR mutation prediction. We
found that c-CYFRA levels correlated with EGFR mu-
tation status. CYFRA 21-1 is cytokeratin 19 fragment
(CK 19), a member of the intermediate filament protein
family, which contributes to the mechanical integrity of
the cell and participates in cell division, motility, and cell-
to-cell contact [16]. EGFR stimulation activates a signaling
cascade, promoting cell division, migration, angiogenesis,
and apoptosis inhibition, which suggests an increase in
structural cytokeratins. This has been confirmed in cell
studies whereby levels of CK 19, [11, 12] CK 6, and CK 16
[16] have been increased in response to EGF stimulation.
We have shown that activating EGFR mutations are
correlated with increased CK 19 expression in human
lung cancers.
In accordance with previous studies, there was no cor-
relation between s-CYFRA levels and EGFR mutation
status. This may be explained by the proposed mecha-
nisms of c-CYFRA release into the serum. Dohmoto et
al. and others showed CK 19 fragment release into the
serum is related to tumor necrosis and cell death mech-
anisms such as cleaving enzymes, caspase-3, and apop-
tosis [17–20]. This may explain the lack of evidence for
correlation between s-CYFRA and EGFR mutation, as
activated EGFR induces apoptosis inhibition which has
been a proposed mechanism for CYFRA 21-1 release
into the serum. Additionally, the half-life of cytokeratin
fragments in the circulation is about 10–15 h [16],
which adds to an additional time variation in the correl-
ation between s-CYFRA levels in patients with an EGFR
mutation. We have clinically shown in a previous study
that s-CYFRA is only weakly correlated with c-CYFRA
levels [8], which may also be corroborating evidence for
this proposed mechanism.
The correlation between EGFR mutation status and
FDG uptake has not been well-established. Previously,
two studies found no statistical difference in FDG uptake
between EGFR mutation and wild-type EGFR [21, 22].
Chung et al. also used metabolic tumor volume and
SUVmax in their analysis, but did not find a significant
correlation between SUVmax and EGFR mutation status
(wild-type SUVmax 9.1 vs mutation SUVmax 8.6) [22].
In contrast, three studies have found a positive correl-
ation, but it is not established which EGFR mutation is
correlated with higher FDG uptake. Moreover, two stud-
ies showed a positive correlation with lower FDG uptake
in EGFR wild-type as compared with mutant EGFR
[23, 24]. Na et al. suggested that using a SUVmax cut-off
of 9.2, 40 % was wild type EGFR, but only 11 % were
EGFR mutation. Mak et al., as also suggested similar trend
in that SUVmax normalized to blood showed that EGFR
mutation showed lower FDG uptake compared to wild
type EGFR (2.9 vs 3.4, respectively). In contrast, one study
found higher FDG uptake in the EGFR-mutated NSCLCs
(SUVmax 10.5) compared with wild-type (SUVmax 8.0)
[25]. In our study, we have shown that SUVmax was sig-
nificantly lower with EGFR mutation status compared
with wild-type, and TLG was lower as well. The major dif-
ference between this study and previous reports is the
homogeneity of the lesions. Due to the prospective nature
of this study in using FNAB, we selected lesions that were
predominately solid and larger than 8 mm, which inciden-
tally reduces SUV-related artifacts such as partial volume
effects found in bronchoalveolar subtype adenocarcin-
omas and in lesions smaller than 5 mm. We suggest that
these conditions resulted in a more reliable estimate of
higher glucose metabolism in wild-type EGFR compared
with mutant EGFR. Previous reports have shown that
FDG PET/CT may be helpful in predicting responses to
TKI therapy [26–28], and the combination of FDG PET/
CT, c-CYFRA, and EGFR mutation status may be helpful
in TKI treatment selection and therapy response.
Recently, lung cancer in female gender and never
smokers has received considerable attention with the
advent of EGFR TKI treatment. Studies have shown
that patients with no smoking history, female sex,
Table 2 Multivariate analysis in the prediction of EGFR mutation
Model 1 Model 2
HR (95 % CI) P value HR (95 % CI) P value
Gender 18.15 (1.44–228.73) 0.025a 39.69 (2.12–741.68) 0.014a
Smoking status 1.44 (0.16–13.24) 0.749 1.58 (0.17–15.02) 0.692
c-CYFRAb 7.58 (1.57–36.61) 0.012a 6.82 (0.03–0.77) 0.023a
SUVmaxc 12.97 (2.20–76.62) 0.005a
Log(TLG)d 24.15 (0–0.38) 0.005a
c-CYFRA cytologic CYFRA 21-1, HR hazard ratio, SUVmax maximum standard uptake value
astatistically significant values of p < 0.05
bc-CYFRA cut-off value: 20.8 ng/ml
cSUVmax cut-off value: 9.6
dLog(TLG) cut-off value: 1.64
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adenocarcinoma histologic type, Asian ethnicity, or
EGFR mutations are predictive of EGFR TKI treat-
ment [29]. In accordance with previous studies, we
have shown in our study a higher distribution of fe-
male gender (67 %) and never smokers (70 %) in
EGFR mutant patients. Among these clinicopathologic
factors, mutations in the EGFR gene have been shown
to have the strongest predictive power. Due to the
added benefit of increased progression-free survival
when using TKI in EGFR mutation-positive patients,
there has been an increasing importance in predicting
EGFR mutations. Multiple randomized phase III trials on
TKI treatment compared to cisplatin based chemotherapy
regimens have shown significant survival benefit of TKI
for patients with EGFR mutation. However, patients with
EGFR wild-type showed significant survival benefit with
cisplatin based therapy, which further places emphasis on
the clinical importance of EGFR mutation analysis
[30–32]. We have shown in our results a high sensitivity
in predicting EGFR mutation when using c-CYFRA levels.
Evaluation of c-CYFRA levels is as rapid as s-CYFRA,
which may provide clinicians with an additional quick and
sensitive method to anticipate which patient may harbor
EGFR mutation.
Our study has some limitations. First, only a relatively
small number of patients were evaluated for EGFR mu-
tation analysis. Only 61 out of 253 patients had an EGFR
mutation, which can be a potential selection bias. How-
ever, it is often unfeasible for clinicians to use EGFR mu-
tational analysis in all patients. In our study, 49 % of
patients had an EGFR mutation, which was similar to
the reported higher incidence of EGFR mutations in
Asians. A recent meta-analysis showed that EGFR muta-
tions in Asians with adenocarcinoma pathology is 47.9 %
(1492 out of 3117 patients) [33], which is much higher
than the reported incidence in European patients (10 %)
[2, 34], Second, the results may be influenced by cut-off
point selection for cytological tumor markers. There are
no normal reference values for tumor marker concentra-
tions in cytological fluid. In our study, we used ROC
curves to determinate the cut-off values of tumor
markers in the cytological fluid. Third, we did not evalu-
ate EGFR-TKI treatment response and survival analysis
according to c-CYFRA levels.
Conclusions
The cytologic tumor marker c-CYFRA was positively as-
sociated with EGFR mutations in NSCLC. C-CYFRA
levels, higher than 20.8 ng/ml, have 83.3 % sensitivity
and 70.5 % accuracy in predicting EGFR mutation status.
In addition, we have also shown that EGFR mutation
has relatively lower glycolysis compared with wild-type
EGFR. Higher levels of c-CYFRA may reflect the cellular
changes associated with activating EGFR mutation, and
further studies are needed to evaluate for the additional
benefit of including c-CYFRA and FDG uptake in
EGFR-targeted therapy evaluation.
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